The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Injectable GHK-Cu, now legally compoundable after the April 2026 reclassification, requires a physicians prescription from a licensed 503A compounding pharmacy following USP 797 sterile compounding standards
Potenza OB causes an increase in heart rate
One study, using objective instruments to measure some aspects of physical function, reported that GLP-1 medications significantly improved physical function compared to placebo
Lipo C works best when administered consistently at the same interval (typically weekly or bi-weekly depending on protocol)
